£112.45

This is the most expensive it has ever been. Walk away.

£112 today · previous high £112 · all-time low £110

Horizons in Cancer Research: Volume 72

Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 71 days · 71 data points (no recent data)

Historical
Generating forecast…
£112.45 £109.27 £109.96 £110.66 £111.35 £112.05 £112.74 25 July 2026 11 August 2026 29 August 2026 15 September 2026 03 October 2026
View at Amazon ↗

Price data last checked 20 day(s) ago - will refresh soon

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 71 days • 3 price levels

Days at Price
Current Price
35 days 29 days 7 days · current 0 9 18 26 35 £110 £111 £112 Days at Price

Price Analysis

Most common price: £110 (35 days, 49.3%)

Price range: £110 - £112

Price levels: 3 different prices over 71 days

Description

Volume 72 discusses the Ewing's sarcoma family of tumours, including classic Ewing's sarcoma of the bone, extraskeletal Ewing's sarcoma and malignant peripheral primitive neuroectodermal tumour of both bone and soft tissue. The following chapter discusses Primary Ewing's sarcoma of the base of the tongue, particularly its diagnosis and treatment. Additionally, the authors examine dual proteasome and histone deacetylase6 inhibitor, dual MDM2 and histone deacetylase inhibitor, and dual bromodomain-containing protein 4 and histone deacetylase inhibitor. The authors go on to examine the genes and proteins involved in mitosis that are proposed as candidates for biomarkers in different types of cancer (colon, lung, prostate, breast and ovarian, among others). The penultimate chapter reviews the published evidence of aromatase inhibitors in breast cancer risk reduction. The recommended patient populations for the use of aromatase inhibitors, expected benefits, adverse effects and monitoring parameters are addressed. The transcription factor and chromatin structure-related aspects of cancer treatment are the focus of the final chapter.

Product Specifications

Barcode

No barcode data available